Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Jeremy D. Shapiro, Subotheni Thavaneswaran, Craig R. Underhill, Kristy P. Robledo, Christos S. Karapetis, Fiona L. Day, Louise M. Nott, Michael Jefford, Lorraine A. Chantrill, Nick Pavlakis, Niall C. Tebbutt, Timothy J. Price, Mustafa Khasraw, Guy A. Van Hazel, Paul M. Waring, Sabine Tejpar, John Simes, Val J. Gebski, Jayesh Desai, Eva Segelov

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study'. Together they form a unique fingerprint.

    Medicine & Life Sciences